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Fate of Transplanted Bone Marrow Derived Mesenchymal Stem 
Cells Following Spinal Cord Injury in Rats by  Transplantation 
Routes
This research was performed to investigate the differences of the transplanted cells’ survival 
and differentiation, and its efficacy according to the delivery routes following spinal cord 
injury. Allogenic mesenchymal stem cells (MSCs) were transplanted intravenously (IV group) 
or intralesionally (IL group) at post-injury 1 day in rats. Behavioral improvement, 
engraftment and differentiation of the transplanted cells and the expression of 
neurotrophic factors of the transplanted groups were analyzed and compared with those 
of the control group. At 6 weeks post-injury, the mean BBB motor scales in the control, IV 
and IL groups were 6.5 ± 1.8, 11.1 ± 2.1, and 8.5 ± 2.8, respectively. Regardless of the 
delivery route, the MSCs transplantation following spinal cord injuries presented better 
behavioral improvement. The differentiations of the engrafted cells were different 
according to the delivery routes. The engrafted cells predominantly differentiated into 
astrocytes in the IV group and on the other hand, engrafted cells of the IL group 
demonstrated relatively even neural and glial differentiation. The expressions of neuronal 
growth factor were significantly higher in the IL group (mean relative optical density, 
2.4 ± 0.15) than those in the control (2.16 ± 0.04) or IV group (1.7 ± 0.23). 
Transplantation of MSCs in the early stage of spinal cord injury gives a significant clinical 
improvement. However, the fate of the transplanted MSCs and expression of neuronal 
growth factors are different along the transplantation route. 
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ORIGINAL ARTICLE
Cell Therapy & Organ Transplantation
INTRODUCTION
Cell transplantation for the regeneration of an injured spinal 
cord would be one of the promising regenerative trials. Cumu-
lative research has demonstrated its feasibility and various stem 
cells have been tried to protect against the secondary damage 
and to enhance the regeneration of a damaged spinal cord (1-6). 
As one trial of this cell therapy, mesenchymal stem cells (MSCs) 
have been highlighted because they can not only be easily har-
vested, expanded and transplanted, but they can also be direct-
ly harvested and transplanted, which obviates the ethical and 
immune rejection problems (7-10). However, several issues need 
to be addressed in order to establish a successful cell therapeu-
tic strategy. Selection of the ideal cell, transplantation method, 
dosage, and the timing of transplantation are still the questions 
that should be addressed. Moreover, knowledge about the sur-
vival, migration, proliferation and differentiation of the trans-
planted cells in the injured site is also essential for successful 
cell therapy for spinal cord injury (SCI). 
  MSCs are known to have a homing effect and to be neuropro-
tective following SCI when they are injected in the early stage of 
SCI (8, 11-13). The suggested neuroprotective effects of MSCs 
for SCI are that they act as an inductor of neurotrophic factor, a 
modulator of inflammation. Moreover, they are suggested to be 
able to replace damaged cells through trans-differentiation (9, 
14-16). However, there is little research regarding the fate of the 
transplanted cells and their neuroprotective effects in different 
transplantation conditions (17, 18). In the present study, MSCs 
were delivered via different transplantation routes in a contu-
sive SCI animal model to investigate whether there are any dif-
ferent in terms of the fate of transplanted MSCs and the altera-
tion of microenvironment of the injured site. 
MATERIALS AND METHODS
Animal Model and group allocation
All of the surgical interventions and the pre-surgical and post-
surgical animal care were provided in accordance with the Lab-Kang E-S, et al.  •  Fate of Transplanted MSCs Following Spinal Cord Injury
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oratory Animal Welfare Act and the Guidelines and Policies for 
Rodent Survival Surgery, as provided by the Animal Studies 
Committee of the Catholic University of Korea (IACUC approv-
al No.2011-0174-01). A total 36 of adult male Sprague-Dawley 
rats (body weight: 250-300 g each) were used in this study. They 
were kept under standardized conditions (4 rat/cage, 20-24°C, 
45%-65% humidity, and a 12 hr of daily light) and given free ac-
cess to food and water throughout the study. Rats were random-
ly assigned to one of the following three groups before opera-
tion; the control group (n = 12, SCI only), the intravenous (IV) 
group (n = 12, SCI + IV administration of MSCs), intralesional 
(IL) group (n = 12, SCI + IL administration of MSCs).
  After random allocation, the rats were anesthetized with ket-
amine (50 mg/kg) and xylazine (2 mg/kg, intraperitoneal). Spi-
nal cord injury was made as described previously (19, 20). Brief-
ly, their backs were shaved and then sterilized with antiseptic 
betadine. Lamincetomies were performed at T9 after exposure 
of the paravertebral muscles from T8-10. All the spinal contu-
sions were induced by a 25 g-cm contusion using the MASCIS 
(Multicenter Animal Spinal Cord Injury Study) impactor (a rod 
weighing 10 g and dropped from a height of 2.5 cm). The 25 g-cm 
lesion was chosen to evaluate the neuroprotective effect of the 
experimental trials in severe SCI. Postoperatively, 5 mg genta-
mycin was administrated intramuscularly. The postoperative 
care procedures involved manual emptying of the bladder twice 
a day during the experiment. 
Preparation of allogenic mesenchymal stem cells
The femoral bone was used to obtain bone marrow. After anes-
thesia, the femoral bone was harvested and both ends of the fem-
oral bone were cut. Bone marrow was aspirated with an 18-guage 
needle and then, diluted to 25 mL with Dulbecco’ Eagles medi-
um (DMEM) (Sigma, St. Louis, MO, USA) supplemented with 
10% heat inactivated fetal bovine serum (FBS) (GibcoBRL, Grand 
island, NY, USA), 2 mM L-glutamate (Sigma), 100 U/mL peni-
cillin and, 0.1 mg/mL streptomycin (Sigma). The bone marrow 
aspirates was plated and then incubated in a humidified atmo-
sphere of 5% CO2 at 37°C. For selecting the MSCs, the nonad-
herent cells were eliminated by replacing the medium 48 hr af-
ter cell seeding. For each passage, the cells were plated at about 
8,000 cells/cm
2 and they were grown to confluency.  
Phenotypic characterization of the MSC and 
transplantation
Flow cytometric analysis of the cultured MSC was performed. 
Briefly, the cells were detached with trypsin-EDTA solution 
(0.05%, 1 min, Sigma) and washed twice with PBS that contain-
ing 0.1% bovine serum albumin. For direct assays, aliquots of 
cells at a concentration of 1 × 10
6 cells per milliliter were immu-
nolabelled at 4°C for 30 min with the following antibodies: FITC-
conjugated CD 45, PE-conjugated CD 29 and CD 73. MSCs are 
known to have the immunophenotype of CD 29 and CD 73 and 
they lack the CD 45 hematopoietic immunophenotype. All the 
monoclonal antibodies were purchased from Pharmingen/Bec-
ton Dickinson (Flanklin Lakes, NJ, USA). As an isotype-matched 
control, mouse immunoglobulin G1-FITC or mouse immuno-
globulin G1-PE was used. The labeled cells were analyzed by a 
FACS Calibur flow cytometer (Becton Dickinson) with the use 
of CellQuest software. 
  Before transplantation, cells were labeled with fluorescent 
membrane-intercalating dye PKH 26 (red fluorescence, 10
-3 M, 
Sigma). PKH 26 is known to have the longest in vivo half-life and 
it is ideal for in vivo cell tracking and cell proliferation studies. 
For the IV transplantation, 1 × 10
6 cells in a 0.5 ml total volume 
were injected through the tail vein 24 hr after SCI and PBS of 
same volume was injected through the tail vein for the control 
group. For the IL transplantation, at post-injury day one the in-
jured sites were re-exposed and a concentration of 1 × 10
6 cells 
in 10 µL was injected using a Hamilton needle. With the help of 
a microscope, even administration was done at the caudal and 
cephalad portions of the injured site. All rats received a daily in-
jection of cyclosporine A (10 mg/kg) intraperitoneally for 5 days 
starting 2 days before surgery.
Immunohistochemical staining for identifying of the 
transplanted cells
To evaluate the survival, homing ability and proliferation of the 
PKH 26 labeled MSCs, 8 rats in each group were randomly as-
signed to undergo tissue harvesting. At 6 weeks post-injury, 
specimens that include spinal cord and spleen were obtained 
after transcardiac perfusion. Spleen was histologically evaluat-
ed to observe the transplanted cells’ entrapment by host im-
mune system. To identify the cell type of the transplanted cells, 
double-labeling studies were performed with the use of prima-
ry antibodies to neurons (NeuN, 1:100, Chemicon, Pemecula, 
CA, USA), oligodendrocytes (CC-1, 1:50, Chemicon) and astro-
cytes (GFAP, 1:50, Chemicon). The details followed the previ-
ously described procedures (20). To quantify the differentiation 
of the transplanted cells in each condition, the cells that were 
exactly co-localized by expressing DAPI, PKH 26 and the cell 
markers NeuN, CC-1, and GFAP were considered as differenti-
ated transplanted MSCs. Two tissue samples from each subject 
were used and on each slide, six fields were randomly selected 
and the high-powered images (× 400) were obtained using con-
focal microscope. The positive cells were counted and the mean 
numbers of each specimen were recorded and the mean num-
bers of each group were compared. We also performed staining 
for type II collagen to investigate the unintended mesenchymal 
differentiation of the transplanted cells. 
Growth factor analysis
Recent studies have demonstrated that stem cell therapy, includ-Kang E-S, et al.  •  Fate of Transplanted MSCs Following Spinal Cord Injury
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ing MSCs for SCI could alleviate secondary damage. The pro-
duction of growth factors by the transplanted cells is suggested 
as one of the possible mechanisms of this. Therefore, we evalu-
ated the expression of neurotrophic growth factors. Four rats in 
each group were used to assess the secretion of growth factors. 
  At 1 week post-injury, the spinal tissues were dissected and 
stored at -80°C. Subsequently, the samples were homogenized 
on ice in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4,  
2 mM EDTA, 1% NP-40, 0.1% Triton X-100, 0.1% SDS, 1 mM  
Na3VO4, 1 mM sodium deoxycholate, 1 mM PMSF, 10 mg/mL 
aprotinin, and 5 mg/mL leupeptin). The lysate was centrifuged 
at 16,000 rpm for 10 min at 4°C. The proteins were separated by 
SDS–polyacrylamide gel electrophoresis and they were trans-
ferred to a polyvinylidene difluoride membrane (Hybond-P, 
Amersham Pharmacia Biotech, Buckinghamshire, UK). The 
membrane was blocked with 5% fat-free dry milk for 1 hr in Tris-
buffered saline (0.1% Tween-20, 20 mM Tris-HCl, 137 mM NaCl, 
pH 7.4) and then it was incubated overnight at 4°C with the pri-
mary antibodies. The antibodies used for immunoblotting were 
as follows: brain-derived neurotrophic factor (BDNF; 1:500, 
Santa Cruz, Santa Cruz, CA, USA), and neuronal growth factor 
(NGF; 1:500; Santa Cruz). After the membranes were washed, 
they were incubated with secondary peroxidase-conjugated 
anti-rabbit or anti-mouse antibodies (Amersham Pharmacia 
Biotech) that were diluted 1:2,000 in Tris-buffered saline with 
0.01% Tween 20. An antibody detection system (ECL, Amersham 
Pharmacia Biotech) was used and the membranes were ex-
posed to X-ray film. The protein band intensities were quanti-
fied with a VDS densitometer (Amersham Pharmacia Biotech).
BBB locomotor rating scale
The BBB locomotor rating scale was used to evaluate the neu-
rological outcomes over the time course of 6 weeks after SCI (21). 
The behavior of each animal in an open field was observed and 
recorded by two researchers. Scores ranging from 0 to 21 were 
recorded every week after injury.
Statistical analysis
All the values in the figures and text are expressed as means ±
S.E.Ms. The results were analyzed by one-way ANOVA followed 
by a Bonferroni post-hoc test for multiple comparisons. A P val-
ue less than 0.05 was considered to be statistically significant.
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Fig. 1. Flow cytomertric analysis of cultured cells with 
CD 45, 73, and 29. The positive expression of CD 73 
and CD 29, and negative expression of CD 45 indicate 
its mesenchymal stem cell lineage.
Fig. 2. Type II collagen expression of the transplanted cells were observed. In both 
transplanted groups, cells with a colocalization of PKH 26 and collagen II were not 
detected. (A) The IV transplanted MSCs do not express type II collagen. (B) Some type 
II collagen expression are noted in the IL group, however, no colocalization are found 
with PKH26 expression (collagen was tagged with green fluorescence, magnification 
× 400, scale bar 20 µm). 
A B
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Fig. 3. Various expressions of neural and glial cell makers of engrafted MSCs. PKH26 positive cells were mainly found at the injured sites. (A) Neuronal differentiation of the 
transplanted MSCs (n = 4, two tissue samples and six fields in each sample). (B) Oligodendrocyte differentiation of the transplanted MSCs. (C) Astrocyte differentiation of the 
transplanted MSCs. Arrow indicates co-localization of PKH and GFAP expression. IV transplanted MSCs were mainly expressed the astrocyte differentiation. The proportion of 
neuronal and oligodendrocyte differentiation were lower than that of IL transplanted MSCs (magnification × 200, scale bar 50 µm). 
A DAPI
IV
IL
NeuN PKH 26 Merged
B DAPI CC-1 PKH 26 Merged
IV
IL
C
50 µm 50 µm
50 µm 50 µm
50 µm
50 µm
50 µm
50 µm
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RESULTS
Characterization of MSC
Before transplantation, the third passage cells were evaluated 
to confirm their phenotype as MSCs. Flow cytometry analysis 
of the MSCs showed positive cell surface markers in CD 29 and 
CD 73. The cultured MSCs lacked the expression of CD 45 (Fig. 
1). This represents that the cultured cells have characteristics of 
MSCs.
Table 1. The mean numbers of engrafted and differentiated cells by transplatation routes
Routes
PKH 26 positive  
( × 200)
Neuron differentiation  
(× 400, PKH26+NeuN)
Oligodendrocyte differentiation 
(× 400, PKH26+CC-1)
Astrocyte differentiation  
( × 400, PKH 26+GFAP)
Other organ  
(spleen)*
IV 30 ± 6.8   9.4 ± 0.9   8.2 ± 1.1 27 ± 1.0 ++
IL 47 ± 7.3 28.4 ± 2.4 20.4 ± 1.3 20 ± 1.3 -
*PKH26 positive cell in spleen.  × 200 and  × 400 represent the magnification rates which were used for cell counting. IV, intravenous transplantation; IL, intralesional trans-
plantation.Kang E-S, et al.  •  Fate of Transplanted MSCs Following Spinal Cord Injury
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Identification of the transplanted cells in vivo
In both treated groups, the transplanted MSCs were found at 
the posterior portion (injured site) of the spinal cord and some 
scattered cells were also observed at the gray and white matter 
adjacent to the injured site. Under magnification (× 400), the cells 
expressing PKH staining coincident with DAPI were counted 
and quantified. In the control group, there were no cells express-
ing PKH 26. The mean numbers of PKH 26 positive cells in the IV 
and IL groups were 30.4 ± 6.9 and, 47 ± 7.3, respectively (Table 
1). The numbers of implanted MSCs were greater in the IL group 
than that in the IV group with statistical significance (P < 0.05). 
Abundant MSCs were found in the spleen in the IV group but 
no MSCs were observed in the spleen of the IL group.
Aberrant differentiation of the transplanted cells
To identify an aberrant differentiation of the transplanted cells 
to mesenchymal lineage, type II collagen staining was performed. 
Primary antibody to type II collagen (1:100, Lab Vision, Fre-
mont, CA, USA) was used. Alexa Fluor 594 was used for immu-
nofluorescence detection of collagen. Neither of the transplant-
ed groups showed collagen expressing transplanted cells (Fig. 2).
Differentiation of the transplanted cells
To observe any differences in the differentiation of transplanted 
cells depending on the transplantation routes, double staining 
was performed and the numbers of cells that were colocalized 
with DAPI, PHK 26 and other cell markers including NeuN, CC-1 
and GFAP were counted. In the IV group, most of the PKH 26 
positive cells were colocalized with GFAP labeling and the num-
bers of cells showing immunofluorescence colocalization with 
NeuN and CC-1 markers were very low. In the IL group, the 
transplanted MSCs were evenly colocalized with GFAP, NeuN 
and CC-1. Table 1 shows the numbers of colocalized expres-
sions of the transplanted cells (Fig. 3). 
Neurotrophic factors expression in the SCI lesion
BDNF and NGF levels in the spinal cord tissue (n = 4, each 
group) were measured. BDNF level in the IL group (mean rela-
tive optical density, 1.70 ± 0.2) were slightly increased com-
pared to those in the control group (1.58 ± 0.22) and the IV 
group (1.39 ± 0.35). However, there was no statistical signifi-
cance (Fig. 4). NGF level in the IL group (mean relative optical 
density, 2.4 ± 0.15) was significantly increased compared to the 
control (2.16 ± 0.04) and the IV group (1.7 ± 0.23) (P < 0.05) 
(Fig. 5).
Behavioral assessment
All the injured rats manifested complete hindlimb paraplegia 
immediately after the operation. In all the groups, the rats grad-
ually recovered varying degrees of motor function over the time 
of observation (Fig. 6). At 6 weeks post-injury, the mean BBB 
motor scales in the control, IV and IL groups were 6.5 ± 1.8, 
Fig. 4. Expression of BDNF. Post-injury 1 week BDNF levels in the spinal cord tissues 
were measured. The relative optical densities in the control, IV and IL groups are 1.58 
± 0.22, 1.39 ± 0.35, 1.70 ± 0.2 respectively. The IL group shows slightly higher 
level compared to those in the control and IV groups. However, BDNF expression does 
not show any significant difference between the groups (n = 4, P > 0.05). 
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Fig. 5. Expression of NGF. Post-injury 1 week NGF levels in the spinal cord tissues 
were measured. The relative optical densities in the control, IV and IL groups are 2.16 
± 0.04, 1.70 ± 0.23, 2.41 ± 0.15 respectively. The IL group shows significantly 
higher level compared to those in the control and IV groups. And there is also signifi-
cant difference between the groups (n = 4, P < 0.05). 
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11.1 ± 2.1, and 8.5 ± 2.8, respectively. The functional recovery 
seen in the rats that underwent MSCs transplantation was sig-
nificantly better than that in the control group (P < 0.05). 
DISCUSSION
There is no doubt that cell based therapy, including stem cells, 
is an attractive and promising therapeutic strategy for many 
clinical conditions that currently lack efficacious treatment. 
However, there are many issues and concerns to be addressed 
before its clinical translation. As one of the efforts to address 
these topics, we tried different transplantation routes of stem 
cells for SCI. The efficacy and fate of the transplanted cells were 
observed according to different transplantation routes. In the 
present study, we used allogenic MSCs. MSCs have been dem-
onstrated to have an ability to “home” into the injured site and 
trans-differentiate into neural lineage cells (13, 22-24). We were 
also able to observe this homing and trans-differentiation abili-
ty even when the MSCs were applied intravenously at the acute 
stage of SCI. Moreover, its results were connected to behavioral 
improvement in the both IV and IL groups compared to the 
control group. 
  Studies on applying MSCs application for various central 
nervous disorders have demonstrated that transplantation of 
MSCs alleviated further tissue damage and it yielded significant 
clinical improvement (7, 10, 12, 25, 26). These results were ex-
plained by the possibilities of a neuroprotective function and a 
tissue repair by the transplanted cells. In most of the reported 
studies, the differentiation of transplanted cells could be ob-
served and to a limited extent, neuron and GFAP positive dif-
ferentiation were reported (10, 25, 27). However, these studies 
did not present the differences depending on the transplanta-
tion route. A few studies that focused on comparing the efficacy 
following MSCs transplantation for SCI demonstrated more   
efficient engrafting of transplanted cells into lesion site when 
grafting by the intralesional or lumbar puncture routes (14, 28, 
29). These studies demonstrated this difference of efficacy only 
through examining the engrafting MSCs volume as counted by 
histological or radioisotope labeling examination. Clinical as-
sessment or the differentiation of transplanted cells has not 
been addressed. As suggested in many studies, intravenous  
delivery has inherent concerns of its efficacy. Although the IV 
route has the advantages of easy and safe delivery, trapping of 
the transplanted cells in the other organs and the high chance 
of exposure to an immune reaction limits its clinical utility. In 
the present study, as predicted and suggested by other previous 
studies, IV delivery showed a lesser number of engrafted MSCs 
as compared to that of IL delivery. Many MSCs were observed 
in the spleen. However, IV delivery showed more effective clini-
cal improvement as compared to that of the control group and 
the IL group. It is hard to conclude from our results that IV de-
livery could result in better clinical improvement in the early 
stage of transplanting MSCs for SCI. However, as other studies 
have reported, IV delivery could be an effective delivery route 
for early MSCs transplantation following SCI. Homing of the 
MSCs to the disrupted blood-spinal cord barrier tissue and 
avoidance of additional injury that can be caused by intrale-
sional delivery could account for these results (9, 12, 25). 
  Homing of MSC into the injured spinal cord is well known 
and stromal derived factor-1 (SDF-1)/CXCR-4 has recently been 
demonstrated to take part in the migration of MSCs (11, 30, 31). 
In our results, even though the absolute number of engrafted 
cells in the IV group was lower than that of the IL group, the de-
gree of behavioral improvement was better in the IV group. This 
phenomenon suggests that the neuroprotective effects of early 
transplanted MSCs do not merely depend on the absolute num-
ber of the engrafted cells. Although it is controversial, some stud-
ies have suggested the possibility of replacement of damaged 
tissue by the transplanted MSCs (32, 33). However, the secre-
tion of neurotrophic factors (BDNF, NGF, and VEGF), the mod-
ulation of inflammation and immune reactions and enhance-
ment of axonal sprouting in the pathologic condition following 
SCI have been recently suggested as the primary effects of MSCs 
transplantation at the early stage, which is beyond their potential 
to differentiate to form glial and neural lineage cells (8, 27, 32). 
  And in terms of clinical results, our study has some limita-
tions. IL transplantation needed the secondary surgery which 
might influence the final clinical results. Further research is 
needed to clarify the neuroprotective mechanism of MSCs trans-
plantation for early stage of SCI.
  In terms of the fate of the transplanted cells, numerous stud-
ies have reported that MSCs have the capability to differentiate 
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Fig. 6. Open field locomotor assessment using Basso-Beattie-Bresnahan scale tested 
at every week after SCI. All subjects show a gradual improvement in hindlimb func-
tion during the 6 week observation period. Stastistical analysis indicated that BBB 
scales in the MSCs transplanted group were significantly higher than those in the 
control group (n = 8, P < 0.05). The rats in the IV group show the highest improve-
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into neuronal cell lineages (5, 10, 24). Even though MSCs were 
intravenously transplanted, the transplanted MSCs expressed 
neuron or glial cell phenotypes. Our immunohistochemical 
data also demonstrated that the transplanted PKH26 positive 
cells were predominantly located at the damaged area. Surpris-
ingly, the phenotype expressions of the transplanted cells are 
different according to the delivery routes. In the intralesionally 
transplanted group, the transplanted cells showed NeuN, CC-1, 
and GFAP positivity. It suggests that the transplanted cells ex-
pressed all the neuronal lineage phenotype differentiation. In 
contrast, the intravenously transplanted MSCs mainly expressed 
GFAP positivity. NeuN and CC-1 expressing MSCs were rarely 
observed. With our results, it is hard to conclude that one deliv-
ery route is superior to the other. However, the intravenous de-
livery route also showed effective neuroprotective results and 
this is supported by the histologic findings and the clinical im-
provement. 
  Preferential astrocytic differentiation of the transplanted 
MSCs has been reported several times (10, 25, 34). Some au-
thors have suggested that differentiation into astrocytes is the 
default pathway for transplanted MSCs or neuronal stem cells 
through in vivo study (22, 35). However, of importance is that 
this predominant astrocyte differentiation of MSCs in models 
of central nervous system injuries has been associated with fa-
vorable functional results. To interpret these results, most au-
thors agree with the hypothesis that differentiation into astro-
cytes is beneficial for early stage injury through the neuropro-
tective functions of astrocytes (34, 35). However, astrocytes are 
known to have a wide variety of biological activities following 
central nervous system injury (20, 36, 37). In the acute phase of 
injury, astrocytes have a major role to maintain and restore ho-
meostasis in the injured site and this is also important to pro-
tect against further damage. On the other hand, in the chronic 
phase, reactive proliferation of astrocytes results in gliosis and 
this gliosis is a major obstacle to regeneration. Therefore, the 
long term effect of this predominant astrocyte differentiation 
remains to be established. 
  In terms of the neurotrophic factors expression, the IL group 
showed higher BDNF and NGF expression compared to those 
in the control and IV groups. As suggested by the previous stud-
ies, this might be related to the absolute number of the engraft-
ed MSCs. However, in this study, the clinical improvement was 
not correlated to the absolute number of the engrafted MSCs, 
and the expression of BDNF and NGF. These findings might be 
also related to the additional injury during the transplantation 
in the intralesional injections. 
  Before stem cell therapy for SCI can be a successful treatment, 
many issues need to be resolved including the optimal delivery 
route and the fate of the transplanted cells. According to our re-
sults, we suggest that early delivery of allogenic MSCs following 
SCI provided favorable behavioral improvement compared to 
the control group. And then the fate of the transplanted MSCs 
and expression of neuronal growth factors following MSCs trans-
plantation are different along the transplantation route. 
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